Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition ↗

June 17, 2025

Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.

Via Benzinga

Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

June 17, 2025

Via Benzinga

Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks ↗

June 16, 2025

The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.

Via Stocktwits

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 02, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics to Participate in Upcoming Investor Conferences

May 28, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

May 14, 2025

From Verve Therapeutics

Via GlobeNewswire

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗

May 07, 2025

CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.

Via Benzinga

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 02, 2025

From Verve Therapeutics

Via GlobeNewswire

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street ↗

April 29, 2025

Via The Motley Fool

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Why Verve Therapeutics Zoomed 40% Higher This Week ↗

April 18, 2025

Via The Motley Fool

Topics Intellectual Property

Unusual volume stocks are being observed in Tuesday's session. ↗

April 15, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 15, 2025

Via Benzinga

Why Verve Therapeutics Is Skyrocketing Today ↗

April 15, 2025

Via The Motley Fool

The market is filled with gapping stocks in Tuesday's session. ↗

April 15, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday ↗

April 15, 2025

Via Benzinga

Assessing Verve Therapeutics: Insights From 4 Financial Analysts ↗

April 14, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

April 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose ↗

April 14, 2025

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH or premature CAD.

Via Benzinga

These stocks are moving in today's pre-market session ↗

April 14, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 14, 2025

Via Benzinga

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

April 14, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

April 11, 2025

From Verve Therapeutics

Via GlobeNewswire

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

April 01, 2025

Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors

From Climb Bio, Inc.

Via GlobeNewswire

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

March 24, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 03, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 03, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

January 13, 2025

From Verve Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.